NEW YORK (GenomeWeb) – Menarini-Silicon Biosystems said today that it has signed an agreement to purchase all the assets and relevant business related to the Cellsearch circulating tumor cell (CTC) system from Janssen Diagnostics for an undisclosed amount.

Cellsearch is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only US Food and Drug Administration-cleared CTC test, and has been approved by the China FDA for use in monitoring breast cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.